← Leaderboards
Shakeel Modak
Sloan-Kettering Inst Can Research
$2,048,034
Attributed
$3,254,568
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $564.4K · FY2008–19$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$1,904,823 · 2
FDA$1,349,745 · 2
By mechanism
R01$2,413,068 · 3
R21$841,500 · 1
Top collaborators
- Katharine C Hsu9 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Katharine C Hsu$29,362,365
- James A Fagin$27,970,638
- Raymond J Muller$2,385,467
- Alan L. Ho$4,883,159
- Thomas Reiner$4,804,085
Others in their field
Top investigators on “Child”
- Barbara Driver · Westat, Inc.$244,454,458
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$195,214,889
- George R Seage · Abt Associates, Inc.$189,009,744
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$170,579,744
Research focus
ChildDiagnosisMonitorTumorResponseDoseChildhoodMalignant NeoplasmsNeuroblastomaToxic EffectTumor EradicationResistanceMonoclonal Antibody 3f8Monoclonal AntibodiesCellsPhase I Clinical TrialsBaseAntigensAllogenicAntibody TherapyCell KillingAntibody -Dependent Cell CytotoxicityAlgorithmsAdverse Effects
Grant awards (11)
Phase I study humanized 3F8 MoAb (IND 112594) and NK cells (IND BB-13399) for neuroblastoma$249,917
R01 · FY2019 · FD
Phase I study humanized 3F8 MoAb (IND 112594) and NK cells (IND BB-13399) for neuroblastoma$249,829
R01 · FY2017 · FD
Phase I study humanized 3F8 MoAb (IND 112594) and NK cells (IND BB-13399) for neuroblastoma$250,000
R01 · FY2016 · FD
Combination immunotherapy for neuroblastoma: model of innate tumor immunity$354,947
R01 · FY2014 · CA
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma$199,999
R01 · FY2014 · FD
Combination immunotherapy for neuroblastoma: model of innate tumor immunity$343,969
R01 · FY2013 · CA
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma$200,000
R01 · FY2013 · FD
Combination immunotherapy for neuroblastoma: model of innate tumor immunity$364,407
R01 · FY2012 · CA
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma$200,000
R01 · FY2012 · FD
Combination of targeted radiotherapy and anti-angiogenesis for resistant neurobla$420,750
R21 · FY2009 · CA · contact PI
Combination of targeted radiotherapy and anti-angiogenesis for resistant neurobla$420,750
R21 · FY2008 · CA · contact PI